Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

ANI Pharma Inc (ANIP)

ANI Pharma Inc (ANIP)
66.99 -0.53 (-0.78%) 04/07/25 [NASDAQ]
66.97 x 2 67.11 x 3
Realtime by (Cboe BZX)
66.97 x 2 67.11 x 3
Realtime 66.99 unch (unch) 16:20 ET
Quote Overview for Mon, Apr 7th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
64.58
Day High
68.41
Open 64.58
Previous Close 67.52 67.52
Volume 580,258 580,258
Avg Vol 409,029 409,029
Stochastic %K 71.74% 71.74%
Weighted Alpha +7.79 +7.79
5-Day Change +0.04 (+0.06%) +0.04 (+0.06%)
52-Week Range 52.50 - 70.00 52.50 - 70.00
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,470,181
  • Shares Outstanding, K 21,774
  • Annual Sales, $ 614,380 K
  • Annual Income, $ -18,520 K
  • EBIT $ 68 M
  • EBITDA $ 150 M
  • 60-Month Beta 0.49
  • Price/Sales 2.42
  • Price/Cash Flow 8.99
  • Price/Book 3.57

Options Overview Details

View History
  • Implied Volatility 69.21% ( +5.87%)
  • Historical Volatility 47.97%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 69.21% on 04/07/25
  • IV Low 22.30% on 05/13/24
  • Put/Call Vol Ratio 0.15
  • Today's Volume 23
  • Volume Avg (30-Day) 92
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 996
  • Open Int (30-Day) 733

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 1.10
  • Number of Estimates 3
  • High Estimate 1.17
  • Low Estimate 0.99
  • Prior Year 0.95
  • Growth Rate Est. (year over year) +15.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
57.72 +16.06%
on 03/11/25
Period Open: 60.62
69.45 -3.54%
on 04/02/25
+6.37 (+10.51%)
since 03/07/25
3-Month
52.74 +27.03%
on 01/13/25
Period Open: 54.38
69.45 -3.54%
on 04/02/25
+12.61 (+23.19%)
since 01/07/25
52-Week
52.50 +27.60%
on 12/19/24
Period Open: 67.65
70.00 -4.30%
on 05/10/24
-0.66 (-0.98%)
since 04/05/24

Most Recent Stories

More News
Is the Options Market Predicting a Spike in ANI Pharmaceuticals (ANIP) Stock?

Investors in ANI Pharmaceuticals, Inc. ANIP need to pay close attention to the stock based on moves in the options market lately. That is because the Apr 17, 2025 $75.00 Put had some of the highest implied...

ANIP : 66.99 (-0.78%)
GRI Stock Down on Public Offering Despite Encouraging IPF Study Data

GRI Bio, Inc.’s GRI shares plummeted 36.9% on April 1 after the company announced the pricing of a public offering of stock of $5 million.Earlier in the day, the stock surged after the company reported...

FOLD : 7.15 (-4.67%)
ANIP : 66.99 (-0.78%)
GRI : 1.4000 (-7.28%)
3 Russell 2000 Stocks in the Doghouse

3 Russell 2000 Stocks in the Doghouse

CENT : 35.09 (-0.40%)
ANIP : 66.99 (-0.78%)
UDMY : 6.04 (-9.17%)
5 High Earnings Yield Value Picks to Counter Market Uncertainty

The S&P 500 index declined more than 5% in the first three months of 2025 amid growing concerns over tariffs, economic uncertainty and the rise of low-cost AI offerings in China. The market is now facing...

HPK : 8.90 (-8.15%)
IHS : 4.40 (-6.58%)
PBI : 7.99 (+0.38%)
IIIN : 23.87 (-0.95%)
ANIP : 66.99 (-0.78%)
ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

ANIP : 66.99 (-0.78%)
5 Top-Ranked Mid-Cap Stocks to Buy for a Stellar Portfolio

Wall Street is suffering from volatility in the first quarter of 2025. Out of the three large-cap indexes, the S&P 500 and the Nasdaq Composite are in negative territory year to date, while the Dow has...

SKYW : 79.64 (-0.74%)
MAT : 15.78 (-4.07%)
CENX : 14.99 (-0.07%)
EAT : 136.64 (+1.16%)
ANIP : 66.99 (-0.78%)
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering

Akebia Therapeutics AKBA recently announced that it is floating a secondary issue of 25 million shares of its common stock to the public at an issue price of $2 per share, amounting to $50 million.The...

CTMX : 0.4315 (-5.29%)
ETNB : 5.49 (-4.85%)
AKBA : 1.7700 (unch)
ANIP : 66.99 (-0.78%)
Elevation Oncology Plunges 42% on Ending Development of Lead Drug

Shares of Elevation Oncology ELEV plunged more than 40% yesterday after reporting disappointing data from a phase I study on its lead pipeline drug EO-3021 for treating advanced, unresectable or metastatic...

CTMX : 0.4315 (-5.29%)
ETNB : 5.49 (-4.85%)
ELEV : 0.2456 (-1.76%)
ANIP : 66.99 (-0.78%)
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets

ANIP : 66.99 (-0.78%)
ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®

ANIP : 66.99 (-0.78%)
Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment

Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment

ELAN : 8.94 (-2.30%)
JAZZ : 106.93 (-2.83%)
VTRS : 7.61 (-0.13%)
ZTS : 149.10 (-1.73%)
ANIP : 66.99 (-0.78%)
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil

Allogene Therapeutics ALLO incurred a loss of 28 cents per share in fourth-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of 34 cents. In the year-ago period, the company had incurred...

ALLO : 1.4300 (-0.69%)
CTMX : 0.4315 (-5.29%)
ETNB : 5.49 (-4.85%)
ANIP : 66.99 (-0.78%)
ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label

ANIP : 66.99 (-0.78%)
Relative Price Strength: A Smart Strategy Amid Market Turmoil

The U.S. stock market, after a stellar run in 2023 and 2024, hit a rough patch in early 2025. February saw a sharp pullback, with the S&P 500 tumbling 1.4% and extending losses into March. Investors are...

OOMA : 11.94 (-1.57%)
ANIP : 66.99 (-0.78%)
MATX : 109.04 (-2.78%)
VIRT : 35.15 (+0.13%)
EVER : 21.15 (-2.35%)
Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks

Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks

VTRS : 7.61 (-0.13%)
AMPH : 25.00 (-6.05%)
ANIP : 66.99 (-0.78%)
AMRX : 7.21 (-2.30%)
Zacks.com featured highlights include ANI Pharmaceuticals, Dana, Pitney Bowes, Priority Technology and Kingstone

For Immediate ReleaseChicago, IL – March 12, 2025 – Stocks in this week’s article are ANI Pharmaceuticals, Inc. ANIP, Dana Inc. DAN, Pitney Bowes PBI, Priority Technology Holdings, Inc. PRTH and...

DAN : 10.87 (-3.46%)
KINS : 15.44 (-1.91%)
PRTH : 6.53 (-0.46%)
PBI : 7.99 (+0.38%)
ANIP : 66.99 (-0.78%)
1 Growth Stock to Target This Week and 2 to Avoid

1 Growth Stock to Target This Week and 2 to Avoid

DECK : 106.13 (+0.10%)
RTX : 117.32 (-0.11%)
ANIP : 66.99 (-0.78%)
5 High Earnings Yield Value Stocks Amid Renewed Recession Fears

The stock market is facing a sharp correction after two years of gains. Major U.S. indexes have entered correction territory, with technology and semiconductor stocks leading the decline. Investor sentiment...

DAN : 10.87 (-3.46%)
KINS : 15.44 (-1.91%)
PRTH : 6.53 (-0.46%)
PBI : 7.99 (+0.38%)
ANIP : 66.99 (-0.78%)
Here's Why Ensign Group Can be a Smart Addition to Your Portfolio

The Ensign Group, Inc. ENSG benefits from a growing aging population, rising demand for rehabilitation services, strategic acquisitions and adequate cash generation abilities. A positive business outlook...

OPCH : 32.87 (-2.00%)
MD : 13.14 (-2.74%)
ANIP : 66.99 (-0.78%)
ENSG : 124.63 (-3.63%)
Corcept Shares Rise More Than 55% in 6 Months: Here's Why

Shares of Corcept Therapeutics Incorporated CORT have rallied 56.4% in the past six months against the industry’s decline of 10.5%.The company’s sole-marketed drug, Korlym (mifepristone), which is...

CORT : 74.65 (+0.27%)
JAZZ : 106.93 (-2.83%)
ANIP : 66.99 (-0.78%)
ORGO : 3.89 (+0.52%)
AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol).The settlement agreement...

JAZZ : 106.93 (-2.83%)
RIGL : 17.04 (-1.16%)
ANIP : 66.99 (-0.78%)
AXSM : 98.50 (-0.36%)
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers

Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers

VTRS : 7.61 (-0.13%)
ANIP : 66.99 (-0.78%)
AMPH : 25.00 (-6.05%)
AMRX : 7.21 (-2.30%)
ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe

ANIP : 66.99 (-0.78%)
Why Is ANI Pharmaceuticals (ANIP) Stock Soaring Today

Why Is ANI Pharmaceuticals (ANIP) Stock Soaring Today

ANIP : 66.99 (-0.78%)
ANI: Q4 Earnings Snapshot

ANI: Q4 Earnings Snapshot

ANIP : 66.99 (-0.78%)
ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Impressive Q4, Stock Soars

ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Impressive Q4, Stock Soars

ANIP : 66.99 (-0.78%)
ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance

ANIP : 66.99 (-0.78%)
Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks

Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks

VTRS : 7.61 (-0.13%)
ANIP : 66.99 (-0.78%)
AMPH : 25.00 (-6.05%)
AMRX : 7.21 (-2.30%)
ANI Pharmaceuticals to Present at Raymond James’ Institutional Investors and Leerink Partners Global Healthcare Conferences in March

ANIP : 66.99 (-0.78%)
Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest

Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest

VTRS : 7.61 (-0.13%)
ANIP : 66.99 (-0.78%)
AMPH : 25.00 (-6.05%)
AMRX : 7.21 (-2.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone...

See More

Key Turning Points

3rd Resistance Point 72.17
2nd Resistance Point 70.29
1st Resistance Point 68.90
Last Price 66.99
1st Support Level 65.63
2nd Support Level 63.75
3rd Support Level 62.36

See More

52-Week High 70.00
Last Price 66.99
Fibonacci 61.8% 63.31
Fibonacci 50% 61.25
Fibonacci 38.2% 59.18
52-Week Low 52.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.